A lean first quarter for venture-backed developers
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.
Biopharma’s venture year ends with another dip
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.
Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Venture investors keep the purse strings tight
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
